相似文献
1
Vogt-Koyanagi-Harada Disease Exacerbation Associated with COVID-19 Vaccine.
Cells. 2022 Mar 16;11(6):1012. doi: 10.3390/cells11061012.
2
Vitiligo as a First Sign of Vogt-Koyanagi-Harada Disease.
Acta Dermatovenerol Croat. 2023 Dec;31(4):229-231.
3
Vogt-Koyanagi-Harada Disease following Covid-19 Vaccine: A Case Report and Literature Overview.
Ocul Immunol Inflamm. 2022 Jul;30(5):1292-1295. doi: 10.1080/09273948.2022.2028291. Epub 2022 Feb 3.
4
Vogt-Koyanagi-Harada Disease Associated with COVID-19 mRNA Vaccine.
Ocul Immunol Inflamm. 2021 Aug 18;29(6):1212-1215. doi: 10.1080/09273948.2021.1974492. Epub 2021 Sep 10.
5
Vogt-Koyanagi-Harada Disease following mRNA-1273 (Moderna) COVID-19 Vaccination.
Ocul Immunol Inflamm. 2022 Jul;30(5):1250-1254. doi: 10.1080/09273948.2022.2053547. Epub 2022 Apr 11.
6
A COVID-19 perspective of Vogt-Koyanagi-Harada disease.
Indian J Ophthalmol. 2023 Jun;71(6):2587-2591. doi: 10.4103/IJO.IJO_172_23.
7
Case report: Bilateral panuveitis resembling Vogt-Koyanagi-Harada disease after second dose of BNT162b2 mRNA COVID-19 vaccine.
Front Immunol. 2022 Sep 29;13:967972. doi: 10.3389/fimmu.2022.967972. eCollection 2022.
8
Vogt-Koyanagi-Harada Relapse after COVID-19 Vaccination.
Ocul Immunol Inflamm. 2022 Jul;30(5):1228-1233. doi: 10.1080/09273948.2022.2027469. Epub 2022 Feb 24.
9
Vogt-Koyanagi-Harada disease following ChAdOx1 nCoV-19 and mRNA-1273 vaccination.
J Fr Ophtalmol. 2023 Mar;46(3):207-210. doi: 10.1016/j.jfo.2022.09.017. Epub 2023 Feb 10.
10
COVID-19 Developed During Systemic Steroid Therapy for Vogt-Koyanagi-Harada Disease: A Case Report.
Ocul Immunol Inflamm. 2023 Aug;31(6):1305-1309. doi: 10.1080/09273948.2023.2200488. Epub 2023 Apr 21.
引用本文的文献
1
Vogt-Koyanagi-Harada Syndrome Following COVID-19 mRNA Vaccination: Th2 to Th1 Transition-related Molecular Machinery.
Acta Derm Venereol. 2024 May 13;104:adv21502. doi: 10.2340/actadv.v104.21502.
2
Vogt-Koyanagi-Harada Disease and COVID.
J Clin Med. 2023 Sep 27;12(19):6242. doi: 10.3390/jcm12196242.
3
Ocular manifestations following COVID-19 vaccination.
J Ophthalmic Inflamm Infect. 2023 Sep 23;13(1):44. doi: 10.1186/s12348-023-00358-x.
4
Correction.
Hum Vaccin Immunother. 2023 Aug;19(2):2259160. doi: 10.1080/21645515.2023.2259160. Epub 2023 Sep 21.
5
Challenges in posterior uveitis-tips and tricks for the retina specialist.
J Ophthalmic Inflamm Infect. 2023 Aug 17;13(1):35. doi: 10.1186/s12348-023-00342-5.
6
Bibliometric analysis of the Vogt‒Koyanagi‒Harada disease literature.
Int Ophthalmol. 2023 Nov;43(11):4137-4150. doi: 10.1007/s10792-023-02815-x. Epub 2023 Aug 8.
7
A COVID-19 perspective of Vogt-Koyanagi-Harada disease.
Indian J Ophthalmol. 2023 Jun;71(6):2587-2591. doi: 10.4103/IJO.IJO_172_23.
8
Clinical features, diagnosis, and management of COVID-19 vaccine-associated Vogt-Koyanagi-Harada disease.
Hum Vaccin Immunother. 2023 Aug 1;19(2):2220630. doi: 10.1080/21645515.2023.2220630. Epub 2023 Jun 6.
9
The Characteristics of COVID-19 Vaccine-Associated Uveitis: A Summative Systematic Review.
Vaccines (Basel). 2022 Dec 28;11(1):69. doi: 10.3390/vaccines11010069.
10
Navigating Coronavirus Disease 2019 Vaccination and Uveitis: Identifying the Rates and Risk of Recurrent Uveitis after Coronavirus Disease Vaccination.
Ophthalmology. 2023 May;130(5):501-508. doi: 10.1016/j.ophtha.2022.12.013. Epub 2022 Dec 17.
本文引用的文献
1
Vogt-Koyanagi-Harada Disease Associated with COVID-19 mRNA Vaccine.
Ocul Immunol Inflamm. 2021 Aug 18;29(6):1212-1215. doi: 10.1080/09273948.2021.1974492. Epub 2021 Sep 10.
2
Vogt-Koyanagi-Harada Syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine.
Int J Retina Vitreous. 2021 Aug 30;7(1):49. doi: 10.1186/s40942-021-00319-3.
3
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021.
MMWR Morb Mortal Wkly Rep. 2021 Jul 9;70(27):977-982. doi: 10.15585/mmwr.mm7027e2.
4
Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, following anti-SARS-CoV-2 vaccination.
J Ophthalmic Inflamm Infect. 2021 Jul 5;11(1):21. doi: 10.1186/s12348-021-00251-5.
5
Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients.
Clin Infect Dis. 2022 Mar 1;74(4):715-718. doi: 10.1093/cid/ciab465.
6
Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination.
Vaccines (Basel). 2021 Apr 29;9(5):435. doi: 10.3390/vaccines9050435.
7
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.
Ann Rheum Dis. 2021 Oct;80(10):1306-1311. doi: 10.1136/annrheumdis-2021-220272. Epub 2021 Mar 24.
8
Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases.
Ann Rheum Dis. 2021 Aug;80(8):1098-1099. doi: 10.1136/annrheumdis-2021-220289. Epub 2021 Mar 23.
9
Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases.
Ann Rheum Dis. 2021 Aug;80(8):1100-1101. doi: 10.1136/annrheumdis-2021-220231. Epub 2021 Mar 19.
10
Ophthalmological Considerations for COVID-19 Vaccination in Patients with Inflammatory Eye Diseases and Autoimmune Disorders.
Ophthalmol Ther. 2021 Jun;10(2):201-209. doi: 10.1007/s40123-021-00338-1. Epub 2021 Mar 6.
Zotero 插件
